INT121136

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 2.98
Pain Relevance 1.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (DDC) small molecule metabolic process (DDC) lyase activity (DDC)
cellular nitrogen compound metabolic process (DDC) cellular amino acid metabolic process (DDC) cytoplasm (DDC)
Anatomy Link Frequency
central nervous system 1
DDC (Homo sapiens)
Pain Link Frequency Relevance Heat
dopamine receptor 15 99.80 Very High Very High Very High
Dopamine 162 99.74 Very High Very High Very High
antagonist 21 99.08 Very High Very High Very High
positron emission tomography 46 98.80 Very High Very High Very High
Central nervous system 8 98.80 Very High Very High Very High
Serotonin 32 94.36 High High
agonist 26 93.96 High High
imagery 23 84.96 Quite High
depression 6 81.16 Quite High
Bioavailability 3 74.64 Quite High
Disease Link Frequency Relevance Heat
Vomiting 16 99.62 Very High Very High Very High
Pressure Volume 2 Under Development 3 99.20 Very High Very High Very High
Disease 156 98.68 Very High Very High Very High
Parkinsonian Disorders 39 95.96 Very High Very High Very High
Hepatotoxicity 3 86.88 High High
Galactorrhea 124 84.76 Quite High
Liver Disease 12 83.52 Quite High
Depression 10 81.16 Quite High
Psychosis 18 79.00 Quite High
Anxiety Disorder 4 77.48 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In PD patients, SPECT and PET studies have shown a progressive loss of DAT and VMAT2 and reduced dopa decarboxylase activity using [18F]-fluoro-dopa PET (Table 2).
Negative_regulation (reduced) of dopa decarboxylase associated with positron emission tomography and disease
1) Confidence 0.57 Published 2010 Journal Environ Health Perspect Section Body Doc Link PMC2920085 Disease Relevance 0.73 Pain Relevance 0.51
That leads to increased dopamine levels in the periphery resulting in side effects, namely postural hypotension, nausea and vomiting.2 Carbidopa is an inhibitor of peripheral AADC.
Negative_regulation (inhibitor) of AADC associated with dopamine, pressure volume 2 under development and vomiting
2) Confidence 0.42 Published 2010 Journal Core Evidence Section Body Doc Link PMC2915499 Disease Relevance 0.53 Pain Relevance 0.20
Two catechol- O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were developed during the 1990's to be used as adjuncts to levodopa (LD) - dopa decarboxylase (DDC) inhibitors in the treatment of Parkinson's disease (PD).
Negative_regulation (inhibitors) of DDC associated with disease
3) Confidence 0.41 Published 2004 Journal J Neural Transm Section Abstract Doc Link 15340869 Disease Relevance 0.28 Pain Relevance 0.04
A large group of medications can raise prolactin levels (Table 2 and Figure 2): drugs variably able of impairing central nervous system (CNS) dopaminergic function, such as false dopamine precursors, inhibitors of L-aromatic aminoacids decarboxylase and dopamine receptor antagonists, drugs enhancing serotoninergic neurotransmission, such as serotoninergic precursors, direct and indirect serotonin agonists and blockers of serotonin reuptake, histamine H2 receptor antagonists (Steiner et al 1976; Polleri et al 1980; Muller et al 1983; Di Renzo et al 1989; Molitch 2005).
Negative_regulation (inhibitors) of L-aromatic aminoacids decarboxylase in central nervous system associated with dopamine, antagonist, dopamine receptor, agonist, central nervous system and serotonin
4) Confidence 0.05 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 1.44 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox